Novel combination of efti with KEYTRUDA ® and chemotherapy generates strong response rates across all PD-L1 expression levels in first line non-small cell lung cancer (1L NSCLC) including 61.7% ORR in ...
Scientists have long had the tools to identify the genes being transcribed in a single cell. Those measurements can uncover cell-to-cell differences that reveal clues about the underpinnings of ...
Cells convert mechanical forces into signals that influence physiological processes, such as exercise strengthening bones. A ...
The federal government employs more than two million people, making it the nation’s largest employer. For many, however, understanding or even being aware of the numerous career paths available in ...
A research team at the City University of New York and the University of Texas at Austin has discovered a way to make ...
Spotty reception isn't just an inconvenience when you're on the road, it can leave you cut off from maps, music and emergency help (unless you've got satellite help). If your GPS locks up or your ...
Mesoblast reported a rise in net revenues from Ryoncil® to US$20.6 million for the September quarter, a 69% increase from the prior quarter. Ryoncil® received FDA approval for pediatric SR-aGvHD, ...
The Mesoblast Ltd (ASX: MSB) share price is in focus today after the company announced a 69% quarter-on-quarter increase in net revenues from its lead product Ryoncil®, reaching US$20.6 million for ...
Orion Oyj-19.62% +27.33% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback